Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Molgramostim→

Molgramostim Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
99283-10-0
Molecular formula
Not available
Molecular weight
Not available
Drug class
Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF)immunostimulant
Mechanism of action
Binds GM-CSF receptors and restores GM-CSF signalling, supporting proliferation and differentiation of haematopoietic progenitor cells and activation of neutrophils, monocytes, macrophages and dendritic cells.
Indications / reported uses
  • Investigational inhaled treatment of pulmonary alveolar proteinosis and other studied pulmonary indications; do not interpret this entry as a universal marketing authorisation.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/molgramostim · https://ec.europa.eu/health/documents/community-register/html/o1685.htm

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF); immunostimulant

Mechanism of action

Binds GM-CSF receptors and restores GM-CSF signalling, supporting proliferation and differentiation of haematopoietic progenitor cells and activation of neutrophils, monocytes, macrophages and dendritic cells.

General use cases

  • Investigational inhaled treatment of pulmonary alveolar proteinosis and other studied pulmonary indications; do not interpret this entry as a universal marketing authorisation.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Molgramostim Environmental Risk Assessment (ERA) (the Molgramostim ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.